Novel Inter ‐omic Analysis Reveals Relationships Between Diverse Gut Microbiota and Host Immune Dysregulation in HLA‐B27‐Induced Experimental Spondyloarthritis
ConclusionsInter ‐omic and network anaylsis of gut microbes and the host immune response in experimental SpA provides an unprecedented view of organisms strongly linked to dysregulated IL‐23, IL‐17, IL‐1, IFN‐γ, and TNF pathways. Functional similarities between these organisms may explain why different ge netic backgrounds exhibit common patterns of immune dysregulation, possibly through perturbation of similar metabolic pathways. These results highlight the power of linking analyses of gut microbiota with the host immune response to gain insights into role of dysbiotic microbes in SpA beyond taxonom ic profiling.This article is protected by copyright. All rights reserved.
Conclusion: Our results show for the first time the relationship between serum levels of galectin and the clinical parameters of patients with RA. Demonstrating their role in pathogenesis, new studies with galectins are needed to assess how they function as a biomarker in RA. PMID: 31428469 [PubMed]
Background: Apremilast is an oral phosphodiesterase 4 inhibitor approved for treatment of psoriasis and psoriatic arthritis (PsAs). The aim of this study was to evaluate the efficacy and safety of apremilast in a real-life cohort of patients with plaque psoriasis.
Introduction: Less than 10 cases of cutaneous panniculitides have been reported as adverse reactions to abatacept, with the most common reactions associated with oral contraceptives, nonsteroidal antiinflammatory drugs, antibiotics, and leukotriene-modifying agents. It is vital to recognize panniculitis drug reactions in rheumatologic patients for their future treatment options and the current understanding of cutaneous panniculitides associated with medications.
Background: The IL-17 receptor blocker brodalumab (BRO) was investigated in PsA in two double-blind, placebo (PBO)-controlled, phase III trials. Although terminated early by sponsor decision, sufficient patients were recruited to allow a meaningful evaluation of efficacy and safety.
Psoriasis is an inflammatory skin disease typically characterized by erythema, plaques and scaling. Proinflammatory cytokines including TNF- α, IL-23, and IL-17 are upregulated in psoriatic lesions and promote hyperproliferation of keratinocytes. Furthermore, psoriasis is seen as a systemic inflammatory disease associated with psoriatic arthritis, obesity and cardiometabolic comorbidities. Obesity negatively affects psoriasis disease se verity by producing proinflammatory adipokines by adipocytes and infiltrated immune cells and aggravates furthermore the cardiovascular risk in psoriasis patients.
Background: Psoriasis, psoriatic arthritis, atopic dermatitis (AD), hidradenitis suppurativa (HS) and chronic urticaria (CU) are associated with sleep disturbances (SD). Validated, disease-specific instruments are needed to assess SD in these populations. This work focuses on the development of the ‘PsO Sleepy-Q’ for psoriasis and ‘PsA Sleepy-Q’ for psoriatic arthritis.
Background: The International Dermatology Outcome Measures has established a core domain set for psoriasis clinical trials, including ‘PsA Symptoms.’ We sought to determine whether patients enrolling in a psoriasis trial should first be screened for PsA and then which measure should be used to assess ‘PsA Symptoms.’
Cutaneous infections with Mycobacterium haemophilum are rare and usually characterized by tender, erythematous, ulcerating skin nodules. The risk of disease from nontuberculosis mycobacterium increases with progressive immunodeficiency. Here, we report a case of cutaneous mycobacterium infection in a patient on chronic immunosuppression for mixed connective tissue disease (MCTD)/interstitial lung disease (ILD). Our patient was receiving azathioprine, hydroxychloroquine sulfate (Plaquenil), and prednisone for MCTD, ILD, and rheumatoid arthritis.
Introduction: Psoriasis (PSO) and psoriatic arthritis (PsA) often affect women of childbearing age; but it is unclear if these women ( ♀) feel able to make informed treatment decisions around pregnancy and breastfeeding. This survey gained insight on disease management and pregnancy, to assess if they feel adequately supported. Methods: Women (18–45 years) with chronic inflammatory diseases from the US, Japan, and Germany, Fran ce, UK, Italy and Spain (EU5) participated in a 20-min online survey (Jul–Oct 2017; InSites Consulting).
Background: Psoriasis and psoriatic arthritis (PsA) are associated with a high prevalence of metabolic syndrome and increased risk of diabetes. Apremilast, an oral phosphodiesterase 4 inhibitor, was efficacious in the treatment of patients (pts) with moderate to severe psoriasis in the phase 3 ESTEEM 1 and 2 (EST) and phase 3b LIBERATE trials and in the treatment of pts with active PsA in the phase 3 PALACE 1 –3 trials (PAL). To explore the potential effect of apremilast on A1c concentrations, we assessed A1c in pts receiving placebo (PBO) or apremilast in a pooled analysis of EST, LIBERATE, and PAL.